Results 31 to 40 of about 70,715 (255)
Janus kinase inhibitors: jackpot or potluck?
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +1 more source
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu +20 more
wiley +1 more source
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong +9 more
wiley +1 more source
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure. [PDF]
The Janus Kinase 2 (JAK2) plays essential roles in transmitting signals from multiple cytokine receptors, and constitutive activation of JAK2 results in hematopoietic disorders and oncogenesis.
Xiaobo Wan +4 more
doaj +1 more source
Janus Kinase 2 Influences Growth Hormone Receptor Metalloproteolysis [PDF]
GH signals through the GH receptor (GHR), a cytokine receptor superfamily member that couples to the cytoplasmic tyrosine kinase, Janus kinase 2 (JAK2). In addition to its role in signaling, we recently implicated JAK2 in the regulation of cell surface GHR abundance by modulation of GHR trafficking and mature GHR stability.
Kimberly, Loesch +7 more
openaire +2 more sources
Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition
Pyoderma gangrenosum (PG) is a rare, autoinflammatory disease leading to painful, hard‐to‐treat ulcers. Besides systemic glucocorticoids, a plethora of classic immunosuppressants, biologics and small molecules have been reported to improve PG disease ...
Sebastian Sitaru +2 more
doaj +1 more source
Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia [PDF]
Abstract The Bcr-Abl tyrosine kinase is the causative factor in most chronic myelogenous leukemia (CML) patients. We have shown that Bcr-Abl is associated with a cluster of signaling proteins, including Janus kinase (Jak) 2, growth factor receptor binding protein 2–associated binder (Gab) 2, Akt, and glycogen synthase kinase (GSK)-3β.
Ajoy K, Samanta +4 more
openaire +2 more sources
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source

